CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma Journal Article
| Authors: | Firestone, R. S.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Qin, W. G.; Patel, D.; Tan, C. R.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. S.; Korde, N.; Maclachlan, K. H.; Landau, H. J.; Scordo, M.; Shah, G. L.; Lahoud, O. B.; Giralt, S.; Murata, K.; Hosszu, K. K.; Chung, D. J.; Lesokhin, A. M.; Usmani, S. Z. |
| Article Title: | CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma |
| Abstract: | Teclistamab, a B-cell maturation antigen (BCMA)- and CD3 -targeting bispeci fic antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but ef ficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune pro filing identi fied that effector CD8 + T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management. |
| Keywords: | memory; antibody; target; subsets; maturation antigen |
| Journal Title: | Blood Advances |
| Volume: | 8 |
| Issue: | 7 |
| ISSN: | 2473-9529 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-04-09 |
| Start Page: | 1600 |
| End Page: | 1611 |
| Language: | English |
| ACCESSION: | WOS:001215169100001 |
| DOI: | 10.1182/bloodadvances.2023011225 |
| PROVIDER: | wos |
| PMCID: | PMC10987849 |
| PUBMED: | 37878808 |
| Notes: | The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PDF. Corresponding MSK authors are Ross S. Firestone and SaadZ. Usmani -- Urvi A. Shah's middle initial is incorrectly listed in the publication Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work